ReviewBiosensors2026
Photoacoustic Imaging for Liver Disease: The Systems and the Molecules.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Liver disease represents a significant global health burden, and its effective management relies on early, accurate diagnosis. Established assessments for liver diseases, ranging from invasive biopsies to conventional noninvasive imaging (e.g., ultrasound, MRI, and CT), are often limited by inadequate specificity, potential safety risks, or unsuitability for dynamic tracking. Photoacoustic imaging (PAI), a hybrid modality that combines optical absorption contrast with deep ultrasonic detection, offers an attractive solution for noninvasive, high-sensitivity, and high-specificity imaging in deep organs such as the liver. This review summarizes recent advances in photoacoustic imaging for liver pathophysiology, beginning with the evolution of imaging systems and extending to the diverse molecules employed for preclinical studies and early clinical trials. Specifically, novel reconstruction algorithms improved the spatial resolution and acquisition speed by up to threefold, Monte Carlo-based fluence compensation increased the deep-tissue signal-to-background ratio by approximately 50%, and a 7-azaindole-modified probe exhibited one-magnitude-higher superoxide-triggered activation than conventional hemicyanine dyes. Furthermore, we discuss key challenges and future perspectives, highlighting the translational potential of PAI as an emerging liver imaging modality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.